Johnson & Johnson on May 11 appointed Thibaut Mongon as the chief executive officer of the consumer health division, which the pharmaceutical giant plans to spin off into a listed company by the end of 2023.
Sanofi reported a series of first-quarter 2022 wins, driven mostly by the success of consumer healthcare (CHC) and the company’s blockbuster Dupixent.
GlaxoSmithKline exceeded expectations for the company’s first-quarter 2022 sales and earnings forecasts. This was largely driven by GSK’s sales of Xevudy, an antibody treatment against COVID-19 it developed with Vir Biotechnology, and the company’s Shingrix vaccine against shingles.
Germany’s Bayer signed a deal to sell the company’s Dr. Scholl’s footcare brand to U.S. private investment firm Yellow Wood Partners for $585 million.
Sanofi will change the organizational structure of two Global Business Units to provide greater focus on operations in mature markets and across emerging markets.
GlaxoSmithKline will not make a play for Pfizer’s consumer health business. The British pharma giant’s decision came one day after another potential buyer, Reckitt Benckiser Group, announced that it would not seek to buy the Pfizer business unit, which is valued between $15 and $20 billion.
Industry insiders say Johnson & Johnson is no longer interested in Pfizer’s $20 billion consumer healthcare business
GlaxoSmithKline Chief Executive Officer Emma Walmsley continues to overhaul the company’s pharmaceutical division. Since assuming GSK’s helm, Walmsley has replaced about 50 of its top managers.
Nestle is buying Canadian vitamin maker Atrium Innovations for $2.3 billion, expanding its presence in consumer healthcare.
GlaxoSmithKline poached veteran drug industry scientist Hal Barron from Alphabet-funded Calico to be its research head.